At the time of referral to the CCTT the patient had metastatic disease to her lungs, mediastinal and hilar nodes, porta hepatis, peritoneum, and liver and subsequently received experimental therapy with mTOR inhibitor sirolimus (4 mg orally daily). The gene discussed is MTOR; the disease is metastatic neoplasm.